Authorized generics have
been the subject of controversy and litigation for many years.
Due to health care reform, It is likely that reimbursement based on
average manufacturer price (AMP) will be coming soon to Medicaid
Although the affordability of generic drugs is well known, utilizing
them appropriately and to their full potential may be challenging.
Loss of market exclusivity, impact of the Hatch-Waxman Act, and substitution and bioequivalence are just some of the forces that will drive the generic medication industry into the future.
Health care spending by the federal government, patients, and
third-party payers is driven by many factors, including the price paid
for the prescription drug dispensed.